Guangzhou Innogen Pharmaceutical Group Co., Ltd (HKG:2591)

Hong Kong · Delayed Price · Currency is HKD

7.72

-0.42 (-5.16%)

Jun 18, 2026, 3:25 PM HKT

Market Cap	3.72B
Revenue (ttm)	146.34M
Net Income	-379.87M
EPS	-0.88
Shares Out	456.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,087,600
Open	8.08
Previous Close	8.14
Day's Range	7.62 - 8.59
52-Week Range	7.69 - 74.00
Beta	n/a
Analysts	Strong Buy
Price Target	31.76 (+311.4%)
Earnings Date	Aug 3, 2026

About HKG:2591

Guangzhou Innogen Pharmaceutical Group Co., Ltd engages in the development of drug engaged in the research, development and commercialization of pharmaceutical products. The company’s products are used for the treatment of metabolic diseases, including diabetes, obesity and overweight, and MASH; and other major central nervous system diseases. The company was incorporated in 2014 and is based in Shanghai, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2014

Employees 193

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2591

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 2591 stock is "Strong Buy." The 12-month stock price target is $31.76, which is an increase of 311.40% from the latest price.

Price Target

$31.76

(311.40% upside)

Analyst Consensus: Strong Buy

Stock Forecasts